We are Trading and Supplying Nefrena Tablets in New Delhi, Delhi, India. A Renal Friendly Supplement.
â¢ Calcium-3-methyl-2-oxo-valerate 67 mg (Î±-ketoanalogue to isoleucine , calcium salt) â¢ Calcium-4-methyl-2-oxo-valerate 101 mg (Î±-ketoanalogue to leucine , calcium salt) â¢ Calcium-2-oxo-3-phenylpropionate 68 mg (Î±-ketoanalogue to phenylalanine , calcium salt) â¢ Calcium-3-methyl-2-oxo-butyrate 86 mg (Î±-ketoanalogue to valine , calcium salt) â¢ Calcium-dl-2-hydroxy-4(methylthio) butyrate 59 mg (Î±-hydroxyanalogue to methionine , calcium salt) â¢ Lysine acetate 105 mg (Eq to lysine 75 mg.) â¢ L-threonine 53 mg â¢ L-tryptophan 23 mg â¢ L-histidine 38 mg â¢ L-tyrosine 30 mg â¢ Total nitrogen content per tablet 36 mg â¢ Calcium content per tablet 1.25 mmol=0.05 gm Dietary protein restriction may improve determinants of CKD progression. However, the extent of improvement and effect of ketoanalogue supplementation are unclear. We conducted a prospective, randomized, controlled trial of safety and efficacy of ketoanalogueâsupplemented vegetarian very lowâprotein diet (KD) compared with conventional lowâprotein diet (LPD). Primary end point was RRT initiation or>50% reduction in initial eGFR. Nondiabetic adults with stable eGFR<30 ml/min per 1.73 m2, proteinuria <1 g/g urinary creatinine, good nutritional status, and good diet compliance entered a run-in phase on LPD. After 3 months, compliant patients were randomized to KD (0.3 g/kg vegetable proteins and 1 cps/5 kg ketoanalogues per day) or continue LPD (0.6 g/kg per day) for 15 months. Only 14% of screened patients patients were randomized, with no differences between groups. Adjusted numbers needed to treat (NNTs; 95% confidence interval) to avoid composite primary end point in intention to treat and per-protocol analyses in one patient were 4.4 (4.2 to 5.1) and 4.0 (3.9 to 4.4), respectively, for patients with eGFR<30 ml/min per 1.73 m2. Adjusted NNT (95% confidence interval) to avoid dialysis was 22.4 (21.5 to 25.1) for patients with eGFR<30 ml/min per 1.73 m2 but decreased to 2.7 (2.6 to 3.1) for patients with eGFR<20 ml/min per 1.73 m2 in intention to treat analysis. Correction of metabolic abnormalities occurred only with KD. Compliance to diet was good, with no changes in nutritional parameters and no adverse reactions. Thus, this KD seems nutritionally safe and could defer dialysis initiation in some patients with CKD - Journal of the American Society of Nephrology.
About the Supplier
Established in 2003, AAR ESS REMEDIES PVT. LTD. has been a leading name in offering top notch Cardiovascular Drugs. Located in New Delhi, Delhi, we offer the best quality Nefrena Tablet to our customers at best prices in the industry.
Nature of Business
Supplier / Trading Company
Number of Employees
Year of Establishment
Monday - Sunday
Send your inquiry directly to this supplierReceiver's Company Name: AAR ESS REMEDIES PVT. LTD.
AAR ESS REMEDIES PVT. LTD.
WZ 13E, LANE NO. 4, Vashisth Park, Pankha Road, New Delhi, Delhi, 110046, India